Literature DB >> 35583234

Can Beta-D-Glucan testing as part of the diagnostic pathway for invasive fungal infection reduce anti-fungal treatment costs?

David O Hamilton1,2, Tosin Lambe3, Alexander Howard4, Patricia Crossey1, Jennifer Hughes1, Rui Duarte3, Ingeborg D Welters1,2.   

Abstract

We performed a cost comparison of the current diagnostic and treatment pathway for invasive fungal infection (IFI) versus a proposed pathway that incorporates Beta-D-Glucan (BDG) testing from the NHS perspective. A fungal pathogen was identified in 58/107 (54.2%) patients treated with systemic anti-fungals in the Critical Care Department. Mean therapy duration was 23 days (standard deviation [SD] = 22 days), and cost was £5590 (SD = £7410) per patient. Implementation of BDG tests in the diagnostic and treatment pathway of patients with suspected IFI could result in a mean saving of £1643 per patient should a result be returned within 2 days. LAY
SUMMARY: Invasive fungal infection increases the risk of death in very sick people. So, treatment is started before test results are known. Beta-D-Glucan (BDG) test is faster than standard blood culture tests. We estimate that using BDG tests in how patients are diagnosed could save about £1643 per patient.
© The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.

Entities:  

Keywords:  anti-fungal stewardship; beta-D-glucan; cost analysis

Mesh:

Substances:

Year:  2022        PMID: 35583234      PMCID: PMC9155161          DOI: 10.1093/mmy/myac034

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   3.747


  18 in total

1.  Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.

Authors:  M Carmen Martínez-Jiménez; Patricia Muñoz; Maricela Valerio; Antonio Vena; Jesús Guinea; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2015-08-25       Impact factor: 5.790

2.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

3.  An investigation of antifungal stewardship programmes in England.

Authors:  Christianne Micallef; Diane Ashiru-Oredope; Sejal Hansraj; David W Denning; Samir G Agrawal; Rohini J Manuel; Silke Schelenz; Rebecca Guy; Berit Muller-Pebody; Rakhee Patel; Philip Howard; Susan Hopkins; Elizabeth Johnson; David A Enoch
Journal:  J Med Microbiol       Date:  2017-10-25       Impact factor: 2.472

Review 4.  Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care.

Authors:  Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2013-01-11       Impact factor: 9.079

5.  Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis.

Authors:  Y-K Pang; M Ip; J H S You
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-29       Impact factor: 3.267

Review 6.  Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.

Authors:  D Harrison; H Muskett; S Harvey; R Grieve; J Shahin; K Patel; Z Sadique; E Allen; R Dybowski; M Jit; J Edgeworth; C Kibbler; R Barnes; N Soni; K Rowan
Journal:  Health Technol Assess       Date:  2013-02       Impact factor: 4.014

7.  Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital.

Authors:  R Rautemaa-Richardson; V Rautemaa; F Al-Wathiqi; C B Moore; L Craig; T W Felton; E G Muldoon
Journal:  J Antimicrob Chemother       Date:  2018-12-01       Impact factor: 5.790

8.  Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010-16.

Authors:  Laura Whitney; Hasan Al-Ghusein; Stephen Glass; Mickey Koh; Matthias Klammer; Jonathan Ball; Jonathan Youngs; Rachel Wake; Angela Houston; Tihana Bicanic
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

9.  Combined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units.

Authors:  Daniele Roberto Giacobbe; Malgorzata Mikulska; Mario Tumbarello; Elisa Furfaro; Marzia Spadaro; Angela Raffaella Losito; Alessio Mesini; Gennaro De Pascale; Anna Marchese; Marco Bruzzone; Paolo Pelosi; Michele Mussap; Alexandre Molin; Massimo Antonelli; Brunella Posteraro; Maurizio Sanguinetti; Claudio Viscoli; Valerio Del Bono
Journal:  Crit Care       Date:  2017-07-10       Impact factor: 9.097

10.  (1,3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial.

Authors:  Gennaro De Pascale; Brunella Posteraro; Sonia D'Arrigo; Giorgia Spinazzola; Rita Gaspari; Giuseppe Bello; Luca Maria Montini; Salvatore Lucio Cutuli; Domenico Luca Grieco; Valentina Di Gravio; Giulia De Angelis; Riccardo Torelli; Elena De Carolis; Mario Tumbarello; Maurizio Sanguinetti; Massimo Antonelli
Journal:  Crit Care       Date:  2020-09-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.